Scribe Therapeutics procures $20m Series A

Alameda, California-based Scribe Therapeutics Inc., a provider of a platform for CRISPR-based genetic medicine, has secured $20 million in Series A funding.

ByIris Dorbian

7 October 2020•1 min read

[data-article-body-skeleton]{display:none!important}

JavaScript is required to read this article. Please enable it in your browser and reload the page.

Deals Healthcare Briefs

Scribe Therapeutics procures $20m Series A

Andreessen Horowitz

Related articles